[go: up one dir, main page]

WO2008082567A1 - Procédé de synthèse d'un inhibiteur de la cetp - Google Patents

Procédé de synthèse d'un inhibiteur de la cetp Download PDF

Info

Publication number
WO2008082567A1
WO2008082567A1 PCT/US2007/026097 US2007026097W WO2008082567A1 WO 2008082567 A1 WO2008082567 A1 WO 2008082567A1 US 2007026097 W US2007026097 W US 2007026097W WO 2008082567 A1 WO2008082567 A1 WO 2008082567A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
crystalline anhydrate
solid
batch
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/026097
Other languages
English (en)
Inventor
Ross A. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of WO2008082567A1 publication Critical patent/WO2008082567A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
    • C07C1/26—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon starting from organic compounds containing only halogen atoms as hetero-atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/10—Preparation of halogenated hydrocarbons by replacement by halogens of hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2529/00—Catalysts comprising molecular sieves
    • C07C2529/04—Catalysts comprising molecular sieves having base-exchange properties, e.g. crystalline zeolites, pillared clays
    • C07C2529/06—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof
    • C07C2529/40—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof of the pentasil type, e.g. types ZSM-5, ZSM-8 or ZSM-11

Definitions

  • This invention relates to a process for synthesizing a chemical compound that inhibits cholesterol ester transfer protein (CETP).
  • CETP cholesterol ester transfer protein
  • CHD coronary heart disease
  • CHD coronary heart disease
  • stroke and peripheral vascular disease represent a truly enormous burden to the health care systems of the industrialized world.
  • CHD coronary heart disease
  • Inhibition of CETP is a promising new approach to reducing the incidence of atherosclerosis.
  • Statins have been important in reducing the incidence of CHD by reducing LDL- cholesterol (the "bad cholesterol"), but are relatively ineffective at raising HDL-cholesterol ("the good cholesterol").
  • CETP inhibitors raise HDL-cholesterol, and may provide a potent new tool for reducing CHD and atherosclerosis in the general population. Administration of both a CETP inhibitor and a statin may be especially valuable for treating and preventing atherosclerosis. Pharmaceuticals containing CETP inhibitors are not currently available.
  • the present invention provides a process for preparing a family of CETP inhibitors exemplified by the compound having formula I. These novel compounds are potent CETP inhibitors:
  • the process is convergent, and concludes with the coupling reaction of intermediates 29 and 30 to yield the methyl ester of Compound I, followed by the hydrolysis of the methyl ester to yield Compound I as a carboxylic acid.
  • the compound of Formula I is isolated by the process disclosed herein as a crystalline anhydrous product which is characterized by x-ray powder diffraction, thermogravimetric analysis (TGA), and differential scanning calorimetry (DSC), and by its solid state carbon-13 and fluorine- 19 NMR spectra.
  • FIG. 1 is a characteristic X-ray powder diffraction pattern of the crystalline anhydrous form of compound I.
  • FIG. 2 is a characteristic TGA curve of the crystalline anhydrous form of compound I.
  • FIG. 3 is a characteristic DSC curve of the crystalline anhydrous form of compound I.
  • FIG. 4 is a characteristic carbon-13 cross-polarization magic-angle spinning (CPMAS) nuclear magnetic resonance (NMR) spectrum of the crystalline anhydrous form of compound I.
  • CPMAS characteristic carbon-13 cross-polarization magic-angle spinning
  • FIG. 5 is a characteristic fluorine- 19 cross-polarization magic-angle spinning (CPMAS) nuclear magnetic resonance (NMR) spectrum of the crystalline anhydrous form of compound I.
  • CPMAS cross-polarization magic-angle spinning
  • EDC is l-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
  • DIP EA is diisopropylethylamine.
  • DMAC dimethylacetamide
  • DMSO dimethylsulfoxide.
  • DMF dimethylformamide.
  • Halogen includes fluorine, chlorine, bromine and iodine.
  • HMPA hexamethylphosphoric triamide
  • HBT 1-Hydroxybenzotriazole
  • 'TP AC is isopropyl acetate.
  • Me represents methyl.
  • NaHMDS sodium hexamethydisilazide
  • TEDA is tetramethylethylenediamine.
  • Weinreb amine is N,O-dimethylhydroxylamine.
  • leaving groups other than the tosylate group of Compound 29 can be used as leaving groups for carrying out the final coupling step to make Compound I. These include but are not limited to Cl, Br, I, benzensulfonate (besylate), methanesulfonate (mesylate), trifluoromethanesulfonate (triflate), and trifluoroacetate.
  • the methyl ester group in Compound 29 can be replaced by other alkyl esters which are also used as protecting groups, such as ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and tert-butyl.
  • reaction is monitored by HPLC and is complete in ca. 2 h.
  • Toluene (20 L) and 0.2 M acetic acid (20 L) are added to the reaction mixture.
  • the two-phase mixture is transferred to a 170 L cylinder.
  • Toluene (20 L) and 0.2 M acetic acid (20 L) are added to the reaction flask and this mixture is also transferred to the 170 L cylinder.
  • the layers are separated, and the organic (upper) layer is washed with 10 wt% aqueous sodium chloride (2 x 40 L) and then with GMP water (40 L).
  • the organic phase is then filtered through a bed of silica gel (3 kg), and the silica gel is rinsed with additional toluene (2 x 20 L) until all of the product is recovered.
  • the toluene solution is batch concentrated to a volume of 20 L and then is flushed with 2 x 50 L portions of heptane. The batch volume is adjusted to 60 L and the bath is warmed to completely dissolve any precipitated product.
  • the batch was seeded with crystals from earlier batches and was allowed to cool to ambient temperature overnight. The batch was cooled to 0 °C and filtered. The wet cake was rinsed with cold heptane (0 °C, 15 L) and dried under nitrogen and vacuum in the funnel, yielding 5667 g of product (90% yield).
  • Aqueous HCl (1.0 M, 20 L) was added to the reaction flask, and the batch was transferred to a 100 L extractor. The lower aqueous layer was separated, and the batch was washed sequentially with 2 x 12 L of l .0 M HCl and then 2 x 12 L of GMP water. The toluene solution was dried over anhydrous sodium sulfate and then filtered thru a sintered glass funnel. The toluene solution was batch concentrated to a volume of 10 L, and then 51 L of heptane was added while maintaining the temperature at 40-45 0 C. The batch was allowed to cool to ambient temperature overnight. The batch was then cooled to -5 °C and filtered. The wet cake was rinsed with cold heptane (-5 0 C, 16 L) and dried under nitrogen and then vacuum in the funnel, yielding 5740 g of product (85% yield).
  • the THF was then removed by distillation at ⁇ 45 °C at reduced pressure.
  • the product slurry was allowed to cool to room temperature, and then was filtered.
  • the cake was washed with water (3 X 500 ml) and toluene (2 X 250 mL) and dried under vacuum with nitrogen sweep for 18 h to give the boronic acid 9 (64.3 g, 91%) as an off-white crystalline solid.
  • a 100 mL Schlenk vessel equipped with a stir bar, nitrogen/vacuum inlet, and septum was charged with boronic acid 9 (6.79 g, 35.3 mmole) and biaryl benzoate 25 (9.45 g).
  • the flask was purged with nitrogen and transferred to a glovebox.
  • a catalyst suspension of bis(acetonitrile)palladium dichloride (107 mg, 0.41 mmole) and 1 ,2-bis(di-t- butylphosphinomethyl) benzene (292 mg, 0.74 mmole) in acetonitrile (35mL) was made as described below and was charged to the Schlenk vessel in a glovebox.
  • the vessel in which the catalyst suspension was made was rinsed with acetonitrile (5 mL); the rinse was transferred into the Schlenk vessel.
  • the catalyst was made in a nitrogen- filled glovebox by charging bis(acetonitrile)palladium dichloride (107 mg) and l,2-bis(di-t-butylphosphinomethyl)benzene (292 mg) into a vessel equipped with a stir bar. Acetonitrile (35mL) was then charged. The resulting suspension was agitated at ambient temperature for -2 hr prior to use. This suspension is stable for several days, but some decrease in selectivity and conversion is observed with suspensions that have been stored for more than a week. The 1.8:1 ratio of phosphine ligand to Pd is important for achieving high regioselectivity and high conversion.
  • Aqueous K 3 PO 4 (15.Og of 50% w/w K 3 PO 4 , 7.5g of K 3 PO 4 ) was charged to the resulting thick slurry at ambient temperature.
  • the Schlenk vessel was then sealed, removed from the glovebox, and attached to a nitrogen bubbler.
  • the resulting biphasic mixture was agitated and warmed in an oil bath which was at 55 °C until the amount of unreacted biaryl benzoate remaining was 1.7 LCAP relative to triaryl benzoate product by HPLC analysis (22 hr).
  • Acetonitrile (40 mL) was added at -30 °C, and the bottom aqueous layer separated.
  • the aqueous layer was back-extracted with acetonitrile (3 mL), and this extract was combined with the main organic layer.
  • the reaction mixture was concentrated to -40% of the original volume while maintaining an external temperature and pressure of 40-42 °C /190-200 mbar.
  • the batch was cooled to -30 0 C, and the organic layer was filtered through a sintered glass funnel directly into the crystallization vessel.
  • the reaction vessel was rinsed with MeCN (17 mL), and the rinses were filtered into the reaction vessel. Once the batch cooled, the triaryl benzoate was observed to begin crystallizing out quickly.
  • the rapidly crystallizing mixture which was in a 100 mL, 3-neck round-bottom flask equipped with mechanical stirrer, nitrogen inlet/bubbler, and addition funnel, was diluted with 43 mL of additional CH 3 CN, giving an assay of ⁇ 6 mL CH 3 CN/g of triaryl benzoate product.
  • Water 25 mL was added over 60 min at ambient temperature to the thick slurry to give -27 vol% water (relative to MeCN).
  • the suspension was agitated at ambient temperature until the concentration of triaryl benzoate in the supernatant reached about 5.5 g /L by HPLC analysis (overnight age).
  • the batch was cooled in an ice bath to ⁇ 2 °C and agitated for about 2 hours until the concentration of triaryl benzoate in the supernatant reached -1.6 g/L.
  • the suspension was filtered on a sintered funnel and the cake was washed with a total of 46 ml of 75:25 v/v of chilled CH 3 CN:water as displacement washes.
  • the cake was dried under vacuum and a nitrogen tent at r.t. until a constant weight was obtained.
  • the overall isolated yield of triaryl benzoate for the reaction was -90% (10.8 g, >99.7 LCAP by HPLC).
  • the solution was filtered through a pad of silica gel (1700 g), and the cloudy suspension became a clear solution.
  • the filter cake was washed with 5.0 L of toluene, and the combined washes were added to a 100-L reactor/extractor.
  • the stirred solution was mixed with 6.0 L of 10% w/w NaHSO 4 (900 g in 9.0 L GMP water) and stirred vigorously.
  • the organic (top) layer was then washed with GMP water (2 x 9.0 L), and the aqueous layers were separated.
  • the pH values of the 2 washes were 1 and 4, respectively.
  • the organic layer was concentrated to an oil and dissolved in 10-14 volumes of 3- 7% toluene in heptane.
  • the organics were heated until the solution became clear and homogeneous (between 60-80 0 C, depending on toluene concentration), then slowly cooled to rt. Seeding of the solution (with seeds obtained from earlier batches ) was conducted at 50 0 C, and crystal growth was immediately observed. After overnight cooling to rt, the mother liquor was decanted, and the crystals were washed with 10.0 L of 10% toluene/heptane followed by 6.0 L heptane. The bright white solid was dried for 72 h under vacuum in a nitrogen tent. Yields were typically 82-88% tosylate 28 (99.8 LCAP).
  • oxazolidinone 30 (1.35kg) and dry DMF (30.8L). The synthesis of oxazolidinone 30 is provided later. After cooling to -15 to -20 0 C, NaHMDS (1.96L of 2M solution) was added, and the mixture was aged 15-30 min. The triaryltosylate 29 (2.2 kg) in DMF was added to the resulting sodium salt of oxazolidinone 30, and the mixture was allowed to warm to 0 to 5 0 C. After the triaryl tosylate was consumed, 2.44 L of 5M HCl was added, followed by 22L of 20% heptane/ethyl acetate. Finally, water (11 L) was added slowly.
  • the layers were separated and then the organic layer was washed with DMF:water twice and then with water twice.
  • the organic layer was assayed for yield and then filtered through a plug of silica gel to remove excess oxazolidinone 30.
  • the solution was then solvent switched to methanol and used in the final step.
  • THF (12 L) was added to a 75 L flask equipped with an overhead stirrer, thermocouple, nitrogen inlet, dropping funnel and a steam pot that contained ca. 12 L of a methanol solution of the triaryl oxazolidinone methyl ester (2190 g, 3 moles). Hydrogen peroxide (1800 mL of a 35 wt% solution) was added. The addition was exothermic, and the batch temperature increased from 16 °C to 23 0 C.
  • Lithium hydroxide monohydrate (378 g, 9 moles) was charged to the reaction vessel, and the batch was heated to 60 °C. The reaction was monitored by HPLC and was complete in 15-16 h. The reaction mixture was cooled to 0-10 °C, and aqueous sodium bisulfite (2185 g/ca. 18 L GMP water) was slowly added over 2 hours to quench the hydrogen peroxide. The addition was very exothermic. The absence of peroxide was confirmed using EM Quant Peroxide test strips.
  • the dried organic phase was transferred thru an in-line filter (1 ⁇ m) to a 100 L flask attached to a batch concentrator.
  • the MTBE was removed and replaced with cyclohexane.
  • the batch volume was adjusted to 20 L.
  • the batch was heated to 50-65 0 C to completely dissolve any precipitated solids, and then was cooled to ca. 60 °C and seeded with crystals obtained from earlier batches.
  • the batch was allowed to cool to ambient temperature overnight to yield a white solid.
  • the white solid was isolated by filtration, rinsed with 2 x 2 L of cyclohexane, and dried under a nitrogen bag with vacuum.
  • the solid obtained at this point is a mixture of cyclohexane solvated and anhydrous triaryl oxazolidinone acid.
  • the amount of cyclohexane present is typically 3-5 wt%.
  • This solvate is converted to the anhydrous material by heating in a vacuum oven at a temperature of 110-135 °C, with the exact temperature depending on the design and size of the oven that is used.
  • the oxazolidinone intermediate 30 is made directly from the chiral starting material CBZ-L-alanine (8) by the 3 -step route shown below.
  • the enantiomer of this compound (4R,5S)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-l,3-oxazolidin-2-one can be made by an analogous route starting from CBZ-D-alanine.
  • Step 1 Conversion of 8 to 9:
  • the Weinreb amide 9 from the previous step (6kg, 22.5 mol) and 3,5- bis(trifluoromethyl)bromobenzene (4.85L, 28.1 mol) are dissolved in anhydrous THF (24L).
  • the solution is purged with nitrogen to remove oxygen.
  • the water content should be ⁇ 500ppm at this point.
  • Atmospheric distillation can be carried out to azeotropically remove water if necessary.
  • the solution is cooled to -10°C and iso-PrMgCl in THF (56.4 mol) is slowly added (2 hours) to the reaction via addition funnel, maintaining a reaction temperature ⁇ -5°C.
  • the solution is allowed to warm to 20°C and aged overnight at 20° C, until the amide is ⁇ 0.5 LCAP.
  • reaction is then cooled to -10°C under nitrogen and is quenched slowly over 2 hours into 5N HCl (14L) that is maintained at 0-5°C.
  • MTBE (12L) is added and the biphasic mixture is agitated for 5 min. After warming to 20°-25°C, it is allowed to settle for 30 min, and then the layers are separated. The organic layer is washed with water twice (12L).
  • the organic layer is vacuum transferred through a 1 -micron in-line PTFE filter into a distillation flask and is then concentrated to ⁇ 12L under vacuum (internal temperature ⁇ 40°C) to a minimum agitated volume.
  • the solution is then azeotropically dried with toluene and taken to a minimum agitated volume again.
  • the solution containing ketone 10 is used directly in the next step.
  • Step 3 Reduction of Ketone 10 to Chiral Oxazolidinone 30:
  • the ketone 10 (6 kg) is heated at 50°C with 0.3 eq of Al(O-i-Pr)3 (79Og) in 12L IPA and 18 L of toluene for 15.5 hours.
  • the solution is cooled to ambient temperature, and solid KOH pellets (1.35 kg) are added slowly with vigorous stirring, while keeping the temperature at ⁇ 25 °C.
  • 33L of IN HCl solution is added to quench the reaction, which is kept at ⁇ 25 0 C. If a rag layer of solids forms, it should be filtered off.
  • the rag layer is racemic oxazolidinone, and removal increases the enantiomeric excess.
  • the organic layer is then washed first with 36L of 0.5N HCl, then with 6L IPA combined with 45L water, and finally with 6L IPA combined with 36L water.
  • the organic layer is transferred via an inline filter.
  • the solvent is switched to heptane (target volume is ⁇ 42L) at -40 °C until ⁇ 2 v% toluene is left. Aging at rt for 2 h gives the solid product 11.
  • the crystalline anhydrous product (anhydrate) having Formula I that is obtained by the process disclosed above is characterized by its X-ray power diffraction pattern, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), and its solid state carbon- 13 and fluorine- 19 NMR spectra.
  • X-ray powder diffraction studies are widely used to characterize molecular structures, crystallinity, and polymorphism.
  • the X-ray powder diffraction pattern of the crystalline anhydrous form (also referred to herein as an anydrate) of Compound I was generated on a Philips Analytical X'Pert PRO X-ray Diffraction System with a PW3040/60 console.
  • a PW3373/00 ceramic Cu LEF X-ray tube emitting K- Alpha radiation (wavelength 1.54187 A) was used as the source.
  • Figure 1 shows an X-ray diffraction pattern for the crystalline anhydrous form of Compound I.
  • the crystalline anhydrous product exhibited characteristic diffraction peaks corresponding to 2-theta values of 4.1, 6.5, 8.3 and 13.7 degrees, corresponding to d-spacings of 21.38A", 13.62A", 10.65A", and 6.44A°.
  • the anhydrous product was further characterized by diffraction peaks corresponding to 2-theta values of 14.7, 16.9, 17.4 and 18.3 degrees, corresponding to d-spacings of 6.03A°, 5.24A°, 5.1OA 0 , and 4.85A".
  • the anhydrous product was further characterized by diffraction peaks corresponding to 2-theta values of 19.2, 22.7, and 25.2 degrees, corresponding to d-spacings of 4.63 A°, 3.92A", and 3.54A".
  • d-spacings 4.63 A°, 3.92A", and 3.54A.
  • FIG. 2 shows a characteristic TGA curve for the crystalline anhydrous form of Compound I.
  • a Perkin Elmer Model TGA 7 or equivalent instrument was used. Experiments were performed under a flow of nitrogen using a heating rate of 10 0 C /min to a maximum temperature of approximately 300 0 C. After automatically taring the balance, 1 to 20 mg of sample was added to the platinum sample pan, the furnace was heated, and the heating program was started. Weight/temperature data were collected automatically by the instrument. Analysis of the results was carried out by selecting the Delta Y function within the instrument software and choosing the temperatures between which the weight loss was to be calculated. Weight losses are reported up to the onset of decomposition/evaporation. A weight loss of 1.1% was observed from ambient temperature to 197.1 0 C that was attributed to removal of residual cyclohexane.
  • Figure 3 shows a characteristic DSC curve for the crystalline anhydrous form (anhydrate) of Compound I.
  • a TA Instruments DSC 2910 or equivalent instrument was used. Samples weighing between 1 and 6 mg were weighed into an open pan. The pan was then crimped and placed at the sample position in the calorimeter cell. An empty pan was placed at the reference position. The calorimeter cell was closed and a flow of nitrogen was passed through the cell. The heating program was set to heat the sample at a heating rate of 10 0 C /min to a temperature of approximately 300 0 C. The heating program was started. When the run was completed, the data were analyzed using the DSC analysis program contained in the system software.
  • This endotherm is preceded by two endotherms of much lower enthalpy - the first with an onset at 152 0 C, a peak at 159.5 0 C and an associated enthalpy of 0.8 J/g, and the second with an onset at 167.8 0 C, peak at 169.8 0 C and an enthalpy of melting of 0.2 J/g.
  • endotherms are associated with the presence of residual cyclohexane in the lattice.
  • the carbon- 13 NMR spectrum utilized proton/carbon- 13 cross-polarization magic-angle spinning with variable-amplitude cross polarization, total sideband suppression, and SPINAL decoupling at 100kHz.
  • the sample was spun at 10.0 kHz, and a total of 1024 scans were collected with a recycle delay of 5 seconds.
  • a line broadening of 10 Hz was applied to the spectra before FT was performed.
  • Chemical shifts are reported on the TMS scale using the carbonyl carbon of glycine (176.03 p.p.m.) as a secondary reference.
  • Figure 4 shows a characteristic solid-state carbon- 13 CPMAS NMR spectrum of the crystalline anhydrous form (anhydrate) of Compound I.
  • the crystalline anhydrous form exhibited characteristic signals with chemical shift values of 131.8, 137.5, and 76.8 p.p.m.
  • the crystalline anhydrous form is further characterized by signals with chemical shift values of 130.2, 122.7, and 40.7 p.p.m.
  • the crystalline anhydrous form is further characterized by signals with chemical shift values of 128.8 and 13.0 p.p.m.
  • the crystalline anhydrous form (anhydrate) is further characterized by signals with chemical shift values of 127.3 and 134.7 p.p.m. Peak assignments and intensities for 10 peaks in the carbon- 13 spectrum are shown in Table 2 below.
  • the solid-state fluorine- 19 NMR spectrum was obtained on a Bruker DSX 500WB NMR system using a Bruker 4 mm H/F/X CPMAS probe.
  • the fluorine- 19 NMR spectrum utilized proton/ fluorine- 19 cross-polarization magic-angle spinning with variable- amplitude cross polarization, and SPINAL decoupling at 62.5kHz.
  • the sample was spun at 15.0 kHz, and a total of 512 scans were collected with a recycle delay of 5 seconds.
  • a line broadening of 10 Hz was applied to the spectrum before FT was performed.
  • Chemical shifts are reported using poly(tetrafluoroethylene) (Teflon®) as an external secondary reference which was assigned a chemical shift of-122 p.p.m.
  • Figure 5 shows a characteristic solid-state fluorine- 19 CPMAS NMR spectrum for the crystalline anhydrous form (anhydrate) of Compound I.
  • the crystalline anhydrous form exhibits characteristic signals with chemical shift values of- 63.4 and - 65.2 p.p.m., with relative intensities of 100% and 87% respectively.
  • Compound I and other compounds made by the process disclosed herein are inhibitors of CETP and have utility in increasing the amount of HDL-cholesterol and reducing the amount of LDL-cholesterol in a patient, preferably a human patient. Increases of HDL- cholesterol and reductions of LDL -cholesterol are believe by practitioners in the field of medicine to be advantageous in reducing atherosclerosis and associated diseases.
  • Compound I is a very potent inhibitor of CETP, having an IC50 value of 5OnM using assays described in
  • the crystalline anhydrate of Compound l is a stable crystalline form which can be formulated by conventional methods well known in the art to make a tablet, capsule or other dosage form having a suitable dose for reducing CETP activity in a patient.
  • a dose may be in the range of 5mg to 250mg, for example 5mg, lOmg, 25mg, 50mg, lOOmg, 150mg, 200mg, or
  • the crystalline anhydrate may also be converted to other forms of the compound, such as pharmaceutically acceptable salts of the carboxylic acid groups, to prepare dosage forms having improved solubility and bioavailability.
  • the crystalline anhydrate of Compound I and other forms of Compound I can also be made into non-conventional formulations that are designed to improve oral bioavailability compared with conventional formulations. All forms of Compound I can be formulated by dissolving them in oils and/or surfactants or dispersing them as non-crystalline dispersions in water soluble polymers, such as polyvinylpyrrolidone) or copolymers of poly(vinylpyrrolidone).
  • An exemplary formulation of the crystalline anhydrate of Compound I comprises a dose of 5 mg, 10 mg, 50 mg, 100 mg, or 150 mg dissolved in a mixture of surfactants, such as polysorbate 80 and Imwitor 742, to make a solution for use in a gelatin capsule. Such doses may be administered once or twice a day. Such formulations are well known to those of skill in the art of pharmaceutical formulations.
  • the formulations can be administered to patients having atherosclerosis, such as patients having ACS (atherosclerotic coronary syndrome), to reduce or reverse the progression of atherosclerosis, thereby reducing mortality in a patient population having ACS.
  • atherosclerosis such as patients having ACS (atherosclerotic coronary syndrome)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La présente invention a trait à un procédé efficace de production d'un composé qui est un inhibiteur de la CETP. L'avant-dernière étape du procédé correspond au couplage d'un dérivé oxazolidinone et d'un composé triphényle donnant l'ester méthylique d'un composé qui est hydrolysé pour donner un inhibiteur actif de la CETP. (1)
PCT/US2007/026097 2006-12-29 2007-12-20 Procédé de synthèse d'un inhibiteur de la cetp Ceased WO2008082567A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87776406P 2006-12-29 2006-12-29
US60/877,764 2006-12-29

Publications (1)

Publication Number Publication Date
WO2008082567A1 true WO2008082567A1 (fr) 2008-07-10

Family

ID=39272686

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026097 Ceased WO2008082567A1 (fr) 2006-12-29 2007-12-20 Procédé de synthèse d'un inhibiteur de la cetp

Country Status (1)

Country Link
WO (1) WO2008082567A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8049015B2 (en) 2008-09-29 2011-11-01 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2012101142A1 (fr) 2011-01-26 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
US20140303380A1 (en) * 2011-10-31 2014-10-09 Merck Sharp & Dohme Corp. Process for a CETP Inhibitor
JP2016506950A (ja) * 2013-01-31 2016-03-07 チョン クン ダン ファーマシューティカル コーポレーション コレステロールエステル転送蛋白質（ｃｅｔｐ）抑制剤としてのビアリールまたは複素環式ビアリール置換シクロヘキセン誘導体化合物
CN106565761A (zh) * 2016-11-15 2017-04-19 贵州大学 一种4‑羧基苯硼酸的制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014413A1 (fr) * 2004-07-02 2006-02-09 Merck & Co., Inc. Inhibiteurs de la cetp
WO2007079186A2 (fr) * 2005-12-30 2007-07-12 Merck & Co., Inc. Inhibiteurs de la cetp

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014413A1 (fr) * 2004-07-02 2006-02-09 Merck & Co., Inc. Inhibiteurs de la cetp
WO2007079186A2 (fr) * 2005-12-30 2007-07-12 Merck & Co., Inc. Inhibiteurs de la cetp

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8338484B2 (en) 2008-02-01 2012-12-25 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8362044B2 (en) 2008-02-01 2013-01-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8049015B2 (en) 2008-09-29 2011-11-01 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
WO2012101142A1 (fr) 2011-01-26 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode d'évaluation du risque d'un sujet de contracter une maladie cardiovasculaire
US20140303380A1 (en) * 2011-10-31 2014-10-09 Merck Sharp & Dohme Corp. Process for a CETP Inhibitor
US9145348B2 (en) * 2011-10-31 2015-09-29 Merck Sharpe & Dohme Corp. Process for synthesizing a CETP inhibitor
JP2016506950A (ja) * 2013-01-31 2016-03-07 チョン クン ダン ファーマシューティカル コーポレーション コレステロールエステル転送蛋白質（ｃｅｔｐ）抑制剤としてのビアリールまたは複素環式ビアリール置換シクロヘキセン誘導体化合物
US9493430B2 (en) 2013-01-31 2016-11-15 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN105143193B (zh) * 2013-01-31 2017-12-15 株式会社钟根堂 作为cetp抑制剂的联芳基或杂环联芳基取代的环己烯衍生化合物
CN106565761A (zh) * 2016-11-15 2017-04-19 贵州大学 一种4‑羧基苯硼酸的制备工艺

Similar Documents

Publication Publication Date Title
US7863307B2 (en) Process for synthesizing a CETP inhibitor
WO2008082567A1 (fr) Procédé de synthèse d'un inhibiteur de la cetp
US20230183235A1 (en) Solid state forms of amg-510 and process for preparation thereof
WO2021236709A1 (fr) Formes à l'état solide de tapinarof
EP4441043A1 (fr) Formes à l'état solide de deucravacitinib et de deucravacitinib hcl, et procédé de préparation de deucravacitinib et d'intermédiaires
US12492213B2 (en) Solid state forms of sep-363856 and process for preparation thereof
WO2024134498A1 (fr) Formes à l'état solide d'aficamten et leur procédé de préparation
TWI399374B (zh) 新穎晶體形式及製備方法以及其醫藥組合物
WO2020168144A1 (fr) Formes à l'état solide de n-[2-(2-{4-[2-(6,7-diméthoxy-3,4-dihydro-2(lh)-isoquinolinyl)éthyl]phényl}-2h-tétrazol-5-yl)-4,5-diméthoxyphényl]-4-oxo-4h-chromène-2-carboxamide et de son sel mésylate
EP4229047A1 (fr) Formes à l'état solide de pralsetinib et leur procédé de préparation
WO2021119223A1 (fr) Forme à l'état solide du lemborexant
US20240246914A1 (en) Solid state form of centanafadine hcl and process for preparation thereof
US10611793B1 (en) Solid state forms of obeticholic acid salts
WO2024171143A1 (fr) Sels et formes solides d'elenestinib
EP4665732A1 (fr) Sels et formes solides d'elenestinib
EP4229057A1 (fr) Formes à l'état solide de lorécivivint
WO2022225712A1 (fr) Formes à l'état solide de firibastat et leurs processus de préparation
WO2025257758A1 (fr) Formes à l'état solide de navacaprant
EP4594313A1 (fr) Formes à l'état solide de denifanstat
WO2020154581A1 (fr) Formes à l'état solide d'un co-cristal de fédovapagon-acide salicylique
HK1257427B (en) A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one
HK1257427A1 (zh) 制备2-吡唑并[1，5-a]吡嗪-2-基吡啶并[1，2-a]嘧啶-4-酮的方法
JPS63196574A (ja) １，３−オキサゾリジン−２−オン誘導体の製法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867902

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867902

Country of ref document: EP

Kind code of ref document: A1